ライフサイエンスコーパス: SIR

1 SIRs comprise palindromic arm sequences separated by sho

2 SIRs did not demonstrate an increased risk of malignancy

3 SIRs did not increase over time for any cancer.

4 SIRs for CUP were high in association with liver (3.94),

5 SIRs for second primary ovarian cancer were elevated ove

6 SIRs were greatest for those treated at age 14 years (47

7 SIR = 1805), pancreatic cancer (risk = 1.5%; SIR = 256), and myeloproliferative neoplasms (risk = 0.7

8 mainly found for liver cancer (risk = 3.5%; SIR = 1805), pancreatic cancer (risk = 1.5%; SIR = 256),

9 strongly related to anal (SIR for men, 21.5; SIR for women, 7.8), vulvar (SIR, 14.8), vaginal (SIR, 5

10 confirmed HPV association (SIR for men, 3.5; SIR for women, 4.8).

11 04; 95% confidence interval [CI], 3.58-9.54; SIR for LLS, 2.12; 95% CI, 1.16-3.56; P < .001).

12 d myeloproliferative neoplasms (risk = 0.7%; SIR = 764).

13 econd cancers was similar to that in SEER 9 (SIR, 3.45; 95% CI, 0.94-8.83), although not statisticall

14 hort was 48.4 (95% CI = 9.73, 141.41) with a SIR for CD within the paediatric EoE cohort of 75.05 (95

15 ed with length of time after surgery, with a SIR of 2.00 (95% CI 1.48-2.64) after 10 years or more.

16 was increased for esophageal adenocarcinoma (SIR, 1.91; 95% CI, 1.31-2.70) and squamous cell carcinom

17 body site and expressed in terms of adjusted SIR ratios with corresponding 95% CIs.

18 termination of age-, sex-, and race-adjusted SIRs using data from a large clinical study and the SEER

19 We calculated age-, sex-, and race-adjusted SIRs, with 95% confidence intervals (CIs), using the Sur

20 After multivariable adjustment, SIRs decreased significantly across 1996-2012 for Kaposi

21 vs patients not exposed to a biologic agent (SIR, 2.17; 95% CI, 0.59-5.56), even when patients were s

22 All SIRs decreased steeply in the course of follow-up time.

23 All SIRs decreased systematically from age below 60 years to

24 No increased risk followed surgery alone (SIR, 0.93; 95% CI, 0.76 to 1.14; n = 99 solid cancers),

25 re observed for acute myeloid leukemia (AML; SIR = 4.9) in Germany and for kidney cancer (2.3), AML (

26 melanoma that could be used to calculate an SIR or SMR in any flight-based occupation.

27 We introduce the framework by developing an SIR model on a simple network as an example.

28 results demonstrate that pFUS+MB induces an SIR compatible with ischemia or mild traumatic brain inj

29 Breast cancer showed an SIR of 1.9 (95% CI, 1.4 to 2.4) and a CR of 14.4 (95% CI

30 istine on alternating weeks (EMA-CO) with an SIR of 0.9 (95% CI, 0.4 to 2.2), but there were signific

31 iagnosis of GW was strongly related to anal (SIR for men, 21.5; SIR for women, 7.8), vulvar (SIR, 14.

32 ded upon the longevity regulators DAF-16 and SIR-2.1.

33 survivors (SIR = 5.3; 95% CI, 3.6 to 7.8 and SIR = 4.1; 95% CI, 2.4 to 6.9, respectively).

34 g SIS (Susceptible-Infected-Susceptible) and SIR (Susceptible-Infected-Recovered) dynamics we investi

35 ts of these filaments to prove that they are SIR-nucleosome filaments.

36 perfusion rates (21%, 48%, and 77% for ASITN/SIR grades of 0 or 1, 2, and 3 or 4, respectively; P < .

37 e MCA territory (32%, 48%, and 69% for ASITN/SIR grades of 0 or 1, 2, and 3 or 4, respectively; P < .

38 linical outcome (11%, 35%, and 49% for ASITN/SIR grades of 0 or 1, 2, and 3 or 4, respectively; P = .

39 Nineteen patients had ASITN/SIR collateral vessel grades of 0 or 1, 63 patients had

40 cal outcome, with 53% of patients with ASITN/SIR grades of 3 or 4 having a good outcome, as compared

41 O-EA), reduces proton irradiation-associated SIR and tumorigenesis.

42 neck cancer with confirmed HPV association (SIR for men, 3.5; SIR for women, 4.8).

43 ng patients with persistent villous atrophy (SIR, 3.78 [CI, 2.71 to 5.12]) than among those with muco

44 onclude by outlining strategies to attenuate SIR, including approaches to rejuvenate HSCs, which may

45 The registry-based SIR for classical HL was 5.3 (95% CI, 3.0 to 8.8), and f

46 Differences between SIRs were assessed using multivariate negative binomial

47 R = 0.93), kidney (SIR = 0.83), and bladder (SIR = 0.77) and for leukemia (SIR = 0.80), whereas an in

48 CI, 5.84 to 10.07), specifically for breast (SIR, 8.92; 95% CI, 5.85 to 13.07), thyroid (SIR, 5.83; 9

49 isks were found for male small bowel cancer (SIR, 251; 95% CI, 177 to 346; CR at 70 years, 12.0; 95%

50 han 50 years with ER-negative breast cancer (SIR, 4.35; 95% CI, 3.5 to 5.4).

51 SMNs, risk was increased for breast cancer (SIR, 5.5; 95% CI, 4.5 to 6.7), renal cancer (SIR, 3.9; 9

52 penile (SIR, 8.2), and head and neck cancer (SIR, 2.8), including subsites of head and neck cancer wi

53 2.39; 95% CI: 1.70, 3.27), prostate cancer (SIR = 1.21; 95% CI: 1.01, 1.44), combined hematopoietic

54 SIR, 5.5; 95% CI, 4.5 to 6.7), renal cancer (SIR, 3.9; 95% CI, 2.0 to 7.5), soft tissue sarcoma (SIR,

55 = 1.15; 95% CI: 1.06, 1.25), thyroid cancer (SIR = 2.39; 95% CI: 1.70, 3.27), prostate cancer (SIR =

56 .6; 95% CI, 1.5 to 4.4), and thyroid cancer (SIR, 1.9; 95% CI, 1.0 to 3.5).

57 was significantly elevated for all cancers (SIR, 7.74; 95% CI, 5.84 to 10.07), specifically for brea

58 combined hematopoietic and lymphoid cancers (SIR = 1.36; 95% CI: 1.07, 1.71), and soft tissue cancers

59 5% CI: 1.07, 1.71), and soft tissue cancers (SIR = 2.26; 95% CI: 1.13, 4.05).

60 CI, 1.31-2.70) and squamous cell carcinoma (SIR, 1.47; 95% CI, 1.10-1.92).

61 r (SIR, 14.8), vaginal (SIR, 5.9), cervical (SIR, 1.5), penile (SIR, 8.2), and head and neck cancer (

62 The shift from the classical SIR framework to one incorporating the environment requi

63 isk of all types of second cancers combined (SIR, 3.40; 95% CI, 1.55-6.45), particularly lymphoma (SI

64 ns were noted for all cancer sites combined (SIR = 1.15; 95% CI: 1.06, 1.25), thyroid cancer (SIR = 2

65 We consider SIR and SIS propagation dynamics on a temporally-extrude

66 increased risk of any cancer, including CRC (SIR, 1.02; 95% CI, 0.33 to 2.39; P = .97).

67 with LLS than in families with sporadic CRC (SIR for sporadic CRC, 0.48; 95% CI, 0.27-0.79; P < .001)

68 n recipients with cholestatic liver disease (SIR 2.78); five of these cases had primary biliary cirrh

69 Persistently elevated SIRs along with decreasing absolute rates over the entir

70 Significantly elevated SIRs of specific SPCs were observed for acute myeloid le

71 Significantly elevated SIRs were observed for NMSC and NHL in those treated wit

72 in 2007-2008 was not significantly elevated (SIR, 1.14 [95% CI, 0.99 to 1.30]; RD, 67 [95% CI, -6 to

73 k of invasive melanoma (n=519) was elevated (SIR=2.20, 95% CI 2.01-2.39), especially for regional sta

74 reased risks of carcinomas of the esophagus (SIR, 1.69; 95% confidence interval [CI], 1.37-2.07; n =

75 hereas significantly increased 40% excesses (SIR, 1.43; 95% CI, 1.18 to 1.73; n = 111 solid cancers)

76 agent methotrexate and folinic acid (MTX-FA; SIR, 0.7; 95% CI, 0.5 to 1.1) and also for patients trea

77 diation (median, 40 Gy) to the mantle field (SIR, 24.2; 95% CI, 20.7 to 28.3).

78 Recently, for SIR-type infections (that produce one epidemic in a clos

79 Further, SIR-PAM achieves 1.5 times finer lateral resolution than

80 primary invasive melanoma also on the head (SIR, 13.32; 95% CI, 10.28-16.98).

81 .12]) than among those with mucosal healing (SIR, 1.50 [CI, 0.77 to 2.62]).

82 ks were increased after 27 AIds; the highest SIRs were noted for chorea minor (8.00), lupoid hepatiti

83 between myopenia, myosteatosis, and the host SIR in patients with operable CRC.

84 of malignancy among patients exposed to IFX (SIR, 1.69; 95% CI, 0.46-4.32) vs patients not exposed to

85 To realize motionless volumetric imaging, SIR-PAM combines two-dimensional Fourier-spectrum optica

86 , leading to further sulfite accumulation in SIR Ri plants.

87 l batches generated promising differences in SIR, potentially useful for tracing the whole ham produc

88 y invasive melanomas diagnosed, resulting in SIRs of 5.42 (95% CI, 5.23-5.61) and 4.59 (4.37-4.82) fo

89 occurrence of second UM was also increased (SIR = 16.90, 95% CI: 9.00-28.90), which likely includes

90 tatistically significant trend of increasing SIRs with increasing number of melanomas in relatives.

91 h an IR microscope and synchrotron infrared (SIR) radiation is provided here.

92 ired SiR expression due to RNA interference (SIR Ri) developed early leaf senescence.

93 (SIR = 0.81), prostate (SIR = 0.93), kidney (SIR = 0.83), and bladder (SIR = 0.77) and for leukemia (

94 ld risks occurred for cancers of the kidney (SIR, 3.37; 95% CI, 1.79 to 5.77), thyroid (SIR, 4.40; 95

95 risk remained significantly elevated for KS (SIR = 35.4; 95% confidence interval [CI], 18.3-61.9), an

96 The largest SIR was among women age less than 50 years with ER-negat

97 , and bladder (SIR = 0.77) and for leukemia (SIR = 0.80), whereas an increased incidence was found fo

98 ers of the head and neck (SIR = 0.78), lung (SIR = 0.81), prostate (SIR = 0.93), kidney (SIR = 0.83),

99 ; 95% CI, 1.55-6.45), particularly lymphoma (SIR, 12.86; 95% CI, 2.65-37.59) and melanoma (SIR, 9.31;

100 mucosa-associated lymphoid tissue lymphoma (SIR, 5.99; 95% CI, 3.19-10.2; n = 13).

101 h the general population for any malignancy (SIR, 4.39; 95% CI, 2.78-6.59) and for any malignancy exc

102 IR, 12.86; 95% CI, 2.65-37.59) and melanoma (SIR, 9.31; 95% CI, 8.75-33.62).

103 first 5-year follow-up after first melanoma: SIR of 6.1 (95% CI, 4.0-9.0) for interval up to 1 year,

104 nificantly increased risk of skin melanomas (SIR = 2.93, 95% CI: 2.23-3.78) and kidney tumors (SIR =

105 found for malignant melanoma among both men (SIR = 1.09) and women (SIR = 1.29) and for ovarian cance

106 variant resolution photoacoustic microscopy (SIR-PAM).

107 Among cases, 102 were multiple myeloma (SIR 1.41) and 38 were plasmacytoma (SIR 7.06).

108 among men for cancers of the head and neck (SIR = 0.78), lung (SIR = 0.81), prostate (SIR = 0.93), k

109 r to that of the general population for NHL (SIR = 1.0; 95% CI, .4-1.8).

110 6.59) and for any malignancy excluding NMSC (SIR, 4.16; 95% CI, 1.67-8.57).

111 aditionally associated with NF1, we observed SIRs of 2,056 (95% CI, 1,561 to 2,658), and 37.5 (95% CI

112 multivariable Poisson regression analysis of SIR ratios, adjusting for 5-year time period of transpla

113 visual chlorophyll degradation in leaves of SIR Ri mutants was accompanied by a reduction of maximal

114 ated longevity is fully abolished by loss of SIR-2.1 and that the effect of ascr#2 requires expressio

115 aphy of silenced chromatin, and the roles of SIR and RNA interference (RNAi) genes in T. delbrueckii.

116 After proton irradiation, a subset of SIR genes (Troy, Sox17, Opg, Faim2, Lpo, Tlr2 and Ptges)

117 of principle evaluation of the viability of SIR for step-scan spectroelectrochemistry.

118 eased mutability is an intrinsic property of SIRs as evidenced by how almost all mutational processes

119 3 were diagnosed with T2D, giving an overall SIR for T2D of 1.66.

120 with colorectal cancer, rendering an overall SIR of 1.60 (95% CI 1.25-2.02).

121 was higher in HIV-infected patients (overall SIR, 2.7; 95% CI, 2.6-2.9), particularly those aged 15-4

122 The overall SIR for hospitalization for sepsis was 5.7 [95% confiden

123 In contrast, the overall SIR in the obese no surgery cohort (containing 373 color

124 The overall SIR remained increased twofold after 1 or more years of

125 The overall SIR was 3.2 (95% confidence interval [CI], 2.8-3.6) but

126 Particularly high overall SIRs were observed in patients with NF1 age < 15 years:

127 vated (p<0.0001 for all) for cancer overall (SIR 1.69, 95% CI 1.67-1.72), AIDS-defining cancers (Kapo

128 cess of HPV-associated malignancies overall (SIR = 1.4, 95% CL: 1.2, 1.8).

129 cess of HPV-associated malignancies overall (SIR = 2.5, 95% CL: 1.9, 3.4).

130 SIR, 5.01 [CI, 3.30 to 7.62]) than a parent (SIR, 1.96 [CI, 1.45 to 2.67]; interaction P < 0.0001).

131 eak, double-peak), we defined a parsimonious SIR-like model with two possible values for intrinsic tr

132 In particular, SIR was 11.1 (95% CI, 5.56 to 19.5) for breast cancer in

133 fy independent relationships between patient SIR and muscle characteristics.

134 nal (SIR, 5.9), cervical (SIR, 1.5), penile (SIR, 8.2), and head and neck cancer (SIR, 2.8), includin

135 were elevated over the entire study period (SIR, 1.24; 95% CI, 1.2 to 1.3), whereas the absolute rat

136 myeloma (SIR 1.41) and 38 were plasmacytoma (SIR 7.06).

137 s lower than that of the general population (SIR 0.51, 95% CI 0.29-0.84).

138 antly higher than in the general population (SIR 1.30, 95% CI 1.06-1.57).

139 tients compared with the general population (SIR [95% confidence interval], 25.4 [11.4-56.4] and 6.7

140 fferent from that in the general population (SIR, 1.01 [95% CI, 0.93-1.09]) and from the risk in the

141 in younger people in the general population, SIRs were highest in younger transplant recipients (p =

142 k (SIR = 0.78), lung (SIR = 0.81), prostate (SIR = 0.93), kidney (SIR = 0.83), and bladder (SIR = 0.7

143 (ASITN)/Society of Interventional Radiology (SIR) collateral vessel grading system, while reperfusion

144 male workers (standardized incidence ratio (SIR) = 0.91, 95% confidence interval: 0.89, 0.93) but no

145 by calculating the standard incidence ratio (SIR) comparing observed cancer incidence in patients wit

146 eady decline in standarized incidence ratio (SIR) for both sexes.

147 resulting in a standardized incidence ratio (SIR) of 4.6 (95% confidence interval [CI], 4.3 to 4.9) i

148 hat reported a standardized incidence ratio (SIR), standardized mortality ratio (SMR), or data on exp

149 The standardized incidence ratio (SIR), with 95% confidence interval (CI), was calculated.

150 al population (standardized incidence ratio [SIR] 1.80, 95%CI 1.51-2.12).

151 t cancer risk (standardized incidence ratio [SIR] = 4.0; 95% CI, 3.0 to 5.3) was observed when compar

152 number of 79 (standardized incidence ratio [SIR], 1.1; 95% CI, 0.9 to 1.3).

153 al population (standardized incidence ratio [SIR], 2.81 [95% CI, 2.10 to 3.67]) and was greater among

154 s a threefold (standardized incidence ratio [SIR], 3.3; 95% confidence interval [CI], 2.8-3.9) increa

155 breast cancer (standardized incidence ratio [SIR], 43.6; 95% CI, 27.2 to 70.3), as did survivors trea

156 We obtained standardized incidence ratios (SIR) and excess absolute risks of SPNs on patients with

157 ratios (SMR), and standard incidence ratios (SIR) for malignancy were calculated.

158 risk-adjusted standardized infection ratios (SIR) to assess the impact of comorbidity adjustment on p

159 The stable isotope ratios (SIR) of the bioelements ((2)H/(1)H, (13)C/(12)C, (15)N/(

160 Standardized incidence ratios (SIRs) adjusted for age, race/ethnicity, and sex were com

161 Standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) were calc

162 expressed as standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs).

163 The standardized incidence ratios (SIRs) and the 5- and 10-year incidence rates were estima

164 nalyzed using standardized incidence ratios (SIRs) and, for SCC, multivariable Poisson regression ana

165 Standardized incidence ratios (SIRs) expressing risk of next melanoma by calculating th

166 Standardized incidence ratios (SIRs) for all SMNs combined and for breast, thyroid, end

167 Standardized incidence ratios (SIRs) for cancer were calculated after the last medical

168 sex-adjusted standardized incidence ratios (SIRs) for CRC in both groups, as well as in their first-

169 egistry-based standardized incidence ratios (SIRs) for different cancers in the first-degree relative

170 Standardized incidence ratios (SIRs) for senile cataract was significantly increased to

171 Standardized incidence ratios (SIRs) for solid tumors were calculated for 12,691 patien

172 Standardized incidence ratios (SIRs) measured the effect of transplantation on cancer r

173 The standardized incidence ratios (SIRs) of autism and ADHD among individuals with a biolog

174 sex-specific standardized incidence ratios (SIRs) of cancer for carriers and noncarriers.

175 sex-adjusted standardized incidence ratios (SIRs) of cancer in families were compared between groups

176 The standardized incidence ratios (SIRs) of diffuse large B-cell lymphoma (DLBCL) and folli

177 to calculate standardized incidence ratios (SIRs) of S aureus bacteremia, with the incidence rate in

178 We used standardized incidence ratios (SIRs) to compare incidence with the general population a

179 nd calculated standardised incidence ratios (SIRs) to measure cancer risk in people with HIV compared

180 incidence and standardised incidence ratios (SIRs) using as standard the general population of Englan

181 Standardized incidence ratios (SIRs) were calculated as the observed numbers of ovarian

182 Standardized incidence ratios (SIRs) were calculated by malignancy type.

183 Standardized incidence ratios (SIRs) were calculated for all periods and separately for

184 Standardized incidence ratios (SIRs) were calculated for CUP patients defined by metast

185 Standardized incidence ratios (SIRs) were calculated for other tumors in patients who h

186 Standardized incidence ratios (SIRs) were calculated for T2D diagnosis in patients with

187 Standardized incidence ratios (SIRs) were calculated to compare cancers diagnosed in re

188 Standardized incidence ratios (SIRs) were calculated to estimate risks for other Lynch

189 Standardized incidence ratios (SIRs) were computed as estimates of the relative risk of

190 Age- and sex-standardized incidence ratios (SIRs) were estimated by race.

191 Standardized incidence ratios (SIRs) were used for comparison with the general populati

192 Standardized incidence ratios (SIRs) were used to assess risk of a specific SPC compare

193 Standardized incidence ratios (SIRs) with 95% confidence intervals (CIs) were calculate

194 sex-specific standardized incidence ratios (SIRs) with corresponding 95% confidence limits (CL) of H

195 Standardized incidence ratios (SIRs), a proxy measure for relative risk, were calculate

196 dence of SNs, standardized incidence ratios (SIRs), excess absolute risk of subsequent malignant neop

197 nd calculated standardized incidence ratios (SIRs).

198 ute risks and standardized incidence ratios (SIRs).

199 l population (standardized incidence ratios [SIRs]) and the non-IVF group (hazard ratios [HRs]).

200 We use reconstituted SIR heterochromatin to characterize the steps in transcr

201 as carried out using selected ion recording (SIR) acquisition mode.

202 pectrometry (MS/MS), selected ion recording (SIR) and multiple reaction monitoring (MRM) and identifi

203 he classic Susceptible, Infected, Recovered (SIR) model focusing on the impact of host demographics.

204 The Susceptible-Infected-Recovered (SIR) model has successfully mimicked the propagation of

205 studying the susceptible-infected-recovered (SIR) model on uncorrelated configuration networks and a

206 ction with a susceptible-infected-recovered (SIR) model.

207 We use a susceptible-infectious-recovered (SIR) model in conjunction with an ensemble adjustment Ka

208 we show a Susceptible-Infectious-Recovered (SIR) model modified to include control measures that all

209 and cp and in the short intergenic regions (SIR).

210 urability depends on the metabolic regulator SIR-2.1, a NAD(+)-dependent histone deacetylase.

211 pendent on the silent information regulator (SIR) complex composed of the Sir2 histone deacetylase an

212 gulated by the silent information regulator (SIR) complex.

213 07, and 2008-2012 periods, with the relative SIRs being 0.42 (95% CI, 0.32-0.55), 0.31 (95% CI, 0.22-

214 observed among these first-degree relatives (SIR, 2.49 [95% CI, 1.95 to 3.19]) than in the background

215 referred to as senescent immune remodeling (SIR).

216 lications to Susceptible-Infectious-Removed (SIR) dynamics).

217 ive sequences termed short inverted repeats (SIRs) have the propensity to form secondary DNA structur

218 ters and the systemic inflammatory response (SIR) in patients with operable primary colorectal cancer

219 dicative of a sterile inflammatory response (SIR) in the parenchyma.

220 an elevated systemic inflammatory response (SIR) is associated with reduced survival in patients wit

221 enescence-associated inflammatory responses (SIRs), which are involved in colon cancer initiation and

222 9; 95% CI, 2.0 to 7.5), soft tissue sarcoma (SIR, 2.6; 95% CI, 1.5 to 4.4), and thyroid cancer (SIR,

223 nt: the "2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management

224 e a detection limit of 36 fmol for step-scan SIR measurements of ferrocyanide.

225 her if the index case patient was a sibling (SIR, 5.01 [CI, 3.30 to 7.62]) than a parent (SIR, 1.96 [

226 Significant SIRs were observed for cancers of the small bowel, ovari

227 were at least two independently significant SIRs or a statistically significant trend of increasing

228 hrough chemosensory pathways and the sirtuin SIR-2.1.

229 eneration models, activation of the Sirtuin, SIR-2.1, was not required, as sir-2.1; dnj-14 double mut

230 5% CI, 3.01 to 10.18), and endometrial SMNs (SIR, 14.08.07; 95% CI, 7.10 to 27.21).

231 terval [CI], 1.37-2.07; n = 95) and stomach (SIR, 1.44; 95% CI, 1.17-1.76; n = 96).

232 -effect meta-analyses were used to summarize SIR and SMR for melanoma in any flight-based occupation.

233 Summary SIR and SMR of melanoma in pilots and cabin crew.

234 The overall summary SIR of participants in any flight-based occupation was 2

235 The summary SIR for cabin crew was 2.09 (95% CI, 1.67-2.62; P = .45;

236 The summary SIR for pilots was 2.22 (95% CI, 1.67-2.93; P = .001; 12

237 ighest among sarcoma and leukemia survivors (SIR = 5.3; 95% CI, 3.6 to 7.8 and SIR = 4.1; 95% CI, 2.4

238 lies with confirmed cases of Lynch syndrome (SIR for Lynch syndrome, 6.04; 95% confidence interval [C

239 Cs, which may open new avenues for targeting SIR in the clinic.

240 We tested SIR differences by AIDS status and over time using Poiss

241 a better predictor of CVD risk factors than SIR.

242 Here, we show that SIRs confer an increase in localized mutability in breas

243 The SIR complex cannot erase H2B-Ub or histone methylation o

244 The SIR complex comprises the NAD-dependent deacetylase Sir2

245 The SIR did not increase with longer time since treatment (>

246 The SIR for all cancer sites combined in 2007-2008 was not s

247 The SIR for colorectal cancer increased with length of time

248 The SIR for colorectal cancer was 4.2 (CI, 2.8 to 6.3).

249 The SIR for CRC also did not differ significantly between fi

250 The SIR for CRC in patients with serrated polyposis (0.51; 9

251 The SIR for EoE in the CD cohort was 48.4 (95% CI = 9.73, 14

252 The SIR for glaucoma was 1.60 after MGUS, 1.76 after WM and

253 The SIR has independent prognostic value, across tumour type

254 The SIR was 1.40 (95% CI, 0.72-2.45) in males and 1.37 (95%

255 The SIR was 1.63 for CUP with metastases in the abdomen when

256 The SIR was 9.21 [95% confidence interval (CI), 1.85-26.91]

257 The SIR was quantified by the preoperative neutrophil to lym

258 the 1980s, as in the decade 2000 to 2010 the SIR increased to 1.13 (95% CI, 1.07-1.19) for men and 1.

259 Although the SIR model has recently been studied in a multilayer netw

260 rized the interactions between Ubp10 and the SIR complex machinery.

261 re-reviewed by a hematopathologist, and the SIR for NLPHL was calculated on the basis of confirmed N

262 The 3-month cancer risk was 8.0% and the SIR was 33 (95% confidence interval, 27-40), compared wi

263 which a histone-binding protein complex [the SIR (silent information regulator) complex] represses ge

264 the basis of confirmed NLPHL diagnoses, the SIR for NLPHL was 19 (95% CI, 8.8 to 36) in the first-de

265 diagnosed >/= 6 months after enrollment, the SIR for all cancers decreased to 1.06 (95% CI: 0.94, 1.1

266 -2.82) did not differ significantly from the SIR for CRC in patients with multiple serrated polyps (0

267 age, graft organ, and sex, a decline in the SIR for SCC was found, with SIR peaking in patients who

268 tion, we reveal that magnesium exists in the SIR-nucleosome filament, with a role similar to that for

269 ; for example, for 2 previous melanomas, the SIR was 2.8 (95% CI, 2.3-3.4) for patients with familial

270 e biochemistry and structural biology of the SIR-chromatin system bring us much closer to a molecular

271 localization patterns of Sir proteins on the SIR-nucleosome filament reflect those patterns on telome

272 The data and EAKF are used to optimize the SIR model and i) estimate critical epidemiological param

273 In the California Cancer Registry, the SIR for risk of all types of second cancers was similar

274 siae, heterochromatin formation requires the SIR complex, which contains subunits with histone-modify

275 he proteomic findings and indicated that the SIR was facilitated through the induction of the NFkappa

276 I) is allowed to initiate transcription, the SIR complex blocks elongation on chromatin while maintai

277 se taking MTX without TNF inhibitor use, the SIR was 3.9 (95% CI 0.4-14).

278 The SIRs remained elevated throughout the follow-up period.

279 Among rescue/recovery workers, the SIRs had significantly increased by 2007-2008 for 3 canc

280 (SIR, 8.92; 95% CI, 5.85 to 13.07), thyroid (SIR, 5.83; 95% CI, 3.01 to 10.18), and endometrial SMNs

281 (SIR, 3.37; 95% CI, 1.79 to 5.77), thyroid (SIR, 4.40; 95% CI, 2.19 to 7.88), and soft tissue (SIR,

282 .40; 95% CI, 2.19 to 7.88), and soft tissue (SIR, 7.49; 95% CI, 3.59 to 13.78).

283 onally active regions present a challenge to SIR complex-mediated de novo heterochromatic silencing d

284 ll (HSC) compartment directly contributes to SIR due to aging-associated alterations in stem cell dif

285 virus (EBV) seronegative at transplantation (SIR 3.93).

286 state cancer risk following transplantation (SIR: 1.21).

287 in kidney cancer risk with transplantation (SIRs: 8.96 in blacks, 5.95 in Hispanics vs. 4.44 in whit

288 ncluding more than 20 years after treatment (SIR, 1.54; 95% CI, 0.96 to 2.33); significantly increase

289 l elevated 35 years or more after treatment (SIR, 3.9; 95% CI, 2.8 to 5.4), and the cumulative incide

290 2.93, 95% CI: 2.23-3.78) and kidney tumors (SIR = 1.91, 95% CI: 1.27-2.76), primarily in those diagn

291 2.39), especially for regional stage tumors (SIR=4.11, 95% CI 3.27-5.09).

292 tion in the 1983-1987 period, the unadjusted SIR for SCC was 102.7 (95%, 85.8-122.1), declining to 21

293 cellular and molecular mechanisms underlying SIR.

294 melanoma within the first year of follow-up (SIR, 5.3 [95% CI, 4.3-6.4]) and afterward remained stead

295 or women, 7.8), vulvar (SIR, 14.8), vaginal (SIR, 5.9), cervical (SIR, 1.5), penile (SIR, 8.2), and h

296 erson-years among rescue/recovery workers vs SIR, 0.92 [95% CI, 0.83 to 1.03]; RD, -45 [95% CI, -106

297 for men, 21.5; SIR for women, 7.8), vulvar (SIR, 14.8), vaginal (SIR, 5.9), cervical (SIR, 1.5), pen

298 a decline in the SIR for SCC was found, with SIR peaking in patients who underwent transplantation in

299 tion had an excess risk of anal cancer, with SIRs of 109.8 (95% CI, 84.6 to 140.3), 49.2 (95% CI, 33.

300 nded on the indication for splenectomy, with SIRs varying from 3.4 (95% CI, 3.0-3.8) for trauma patie

301 anoma among both men (SIR = 1.09) and women (SIR = 1.29) and for ovarian cancer in women (SIR = 1.32)

302 SIR = 1.29) and for ovarian cancer in women (SIR = 1.32).

303 rval: 0.89, 0.93) but not in female workers (SIR = 0.99, 95% confidence interval: 0.95, 1.03).

304 ceive a diagnosis of SMN after age 40 years (SIR, 2.2; 95% CI, 1.9 to 2.5).

305 ceived a diagnosis at younger than 40 years (SIR, 4.7 [95% CI, 3.9-5.6]), and we found a notable risk

306 6-2.9), particularly those aged 15-44 years (SIR, 4-6).